Clinical trials: Antipsychotic Agents
Depressive Disorder, Depressive Disorder, Major
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
The purpose of this study is to evaluate the effectiveness and safety of risperidone to augment SSRI therapy in patients with treatment-resistant depression and to demonstrate the long-term maintenance effect of risperidone as…
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depression
- Trial name
- NCT00044681
- Testing
- risperidone
- Volunteers
- 258 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe and well tolerated.
- Trial name
- NCT00361166
- Testing
- ACP-103
- Where
- 17 sites in United States, Brazil
- Volunteers
- 400 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine
The investigators hypothesis is that an antipsychotic drug combination of low-dose olanzapine plus low-dose trifluoperazine is similar to regular-dose olanzapine monotherapy in efficacy and safety for treatment of…
- Trial name
- NCT02704962
- Testing
- full-dose olanzapine
- Where
- 2 sites in Taiwan
- Volunteers
- 94 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Schizophrenia
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
- Trial name
- NCT01908192
- Testing
- NaBen®
- Where
- 23 sites in United States, Taiwan
- Volunteers
- 60 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Depression
Risperidone and Suicidality in Major Depressive Disorder
The purpose of this trial is to investigate the efficacy of risperidone as an adjunct to an antidepressant treatment in the acute management of suicidality during an episode of major depressive disorder.
- Trial name
- NCT00167154
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Schizophrenia
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
- Trial name
- NCT00977522
- Testing
- PF-03463275
- Where
- 37 sites in United States
- Volunteers
- 207 people
- Sponsor
- Pfizer
Schizophrenia, Schizoaffective Disorder
The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy
Background: Among individuals with schizophrenia, there is an increased prevalence of obesity, dyslipidemia ,diabetes mellitus and related conditions such as cardiovascular disease.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01215383
- Where
- Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ziv Hospital
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of different dosages (from 3 mg/day to 12 mg/day) of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute…
- Trial name
- NCT00412373
- Testing
- Paliperidone ER
- Where
- 44 sites in United States, India and 4 more
- Volunteers
- 307 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the time for patients to relapse when switched from an oral antipsychotic to one of two doses of long-acting risperidone injection (shots).
- Trial name
- NCT00297388
- Testing
- Risperidone, long-acting injectable
- Volunteers
- 40 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anticholinergic Delirium, Clozapine Poisoning
Rivastigmine as an Antidote for Clozapine-induced Central Nervous System Depression and Delirium
This study aims to evaluate the clinical efficacy and safety of rivastigmine in reversing the full spectrum of anticholinergic delirium including hypoactive delirium which is presented with CNS depression and hyperactive or…
- Conditions
- Anticholinergic Delirium, Clozapine Poisoning, Antipsychotic Toxicity, CNS Depression
- Trial name
- NCT07545382
- Testing
- Rivastigmine
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Schizophrenia, Psychotic Disorders
The Effects of Risperidone and Olanzapine on Thinking
The goal of this research is to find ways to maximize the benefits of antipsychotic medications for cognition. Hypothesis: Risperidone and olanzapine will show greater benefits than conventional medications on assessments of…
- Trial name
- NCT00108368
- Testing
- Risperidone, Olanzapine
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Schizoaffective Disorder
Improving Antipsychotic Adherence Among Patients With Serious Mental Illness
This is a randomized controlled trial examining the effectiveness of a pharmacy-based intervention designed to improve adherence with antipsychotic medications among patients with serious mental illness.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00057135
- Testing
- Unit of use medication packaging, Mailed reminders to patient when medication refills are due, Note to Mental Health Provider when refill is overdue
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment
- Trial name
- MOZART (NCT00649844)
- Testing
- Clozapine, Ziprasidone
- Where
- 22 sites in Italy
- Volunteers
- 147 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Sensory Gating
Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole
The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to…
- Trial name
- NCT00567099
- Testing
- Aripiprzole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New Mexico VA Healthcare System
Schizophrenia
Randomized Withdrawal Study in Patients With Schizophrenia
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
- Trial name
- NCT06961968
- Testing
- iloperidone
- Where
- 22 sites in United States
- Volunteers
- 400 people
- Sponsor
- Vanda Pharmaceuticals
Schizophenia Disorder, Schizoaffective Disorder
Exercise and Olanzapine-samidorphan
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic…
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
- Trial name
- NCT06740890
- Testing
- Olanzapine-samidorphan + exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder, Medication Adherence
CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)
This is a prospective study using customized adherence enhancement (CAE) and long-acting injectable (LAI) antipsychotic in 30 individuals with bipolar disorder (BD) at risk for treatment non-adherence.
- Conditions
- Bipolar Disorder, Medication Adherence, Medication Non Adherence
- Trial name
- NCT03408873
- Testing
- Abilify Maintena, Customized Adherence Enhancement (CAE)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Martha Sajatovic
Delirium, Impaired Cognition
The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study
The long-term objective of the MIND-USA (Modifying the Impact of ICU-Induced Neurological Dysfunction-USA) Study is to define the role of antipsychotics in the management of delirium in vulnerable critically ill patients.
- Conditions
- Delirium, Impaired Cognition, Long Term Psychologic Disorders
- Trial name
- MIND-USA (NCT01211522)
- Testing
- Haloperidol, Ziprasidone
- Where
- 16 sites in United States
- Volunteers
- 566 people
- Sponsor
- Vanderbilt University Medical Center
Psychotic Disorder, Schizophrenia
Gut Microbiome in AP Naive
Antipsychotic (AP) medications are currently the cornerstone of treatment for schizophrenia (SCZ), with off-label prescription rapidly increasing in youth, with an established two-fold increase in standardized mortality ratio…
- Trial name
- NCT03414151
- Testing
- Observation
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia
The purpose of this study is to examine the long-term economic, functional and clinical outcomes in schizophrenia patients who require a change in antipsychotic treatment, and are changed to either paliperidone extended release…
- Trial name
- POST (NCT00488891)
- Testing
- Paliperidone ER, Atypical antipsychotics (AAP)
- Volunteers
- 43 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC